Alberto Martinez

Alberto has 15 years’ experience in the pharmaceutical industry, having started his career as a sales person with Janssen in Spain. He joined the Mundipharma network of independent associated companies in 2003. Since that time, he has performed a number of key roles, including as Marketing Manager Analgesics at Mundipharma International Limited, a member of the network providing certain pre- and post-launch support to other members, primarily in the European region. He was also General Manager of Mundipharma Spain, where he led a corporate turnaround between 2008 and 2014, leading to the company achieving #1 Great Places to Work where it remains to date. Alberto was also previously the Managing Director of the network’s UK entity, Napp Pharmaceuticals. Prior to his current role, he was appointed Regional Director of Northern Europe for the Mundipharma network and in October 2016 he was given additional responsibility as European Director of Commercial Operations.

Alberto is now focused on driving forward the business through strategic priorities that include expanding and diversifying the network’s product portfolio ensuring the network is best placed to secure alliance opportunities at all stages of asset maturity across the commercial platforms of specialist driven primary care, speciality care and established brands.

He holds a PhD from Granada University and an Executive MBA from IE Business School, Spain.

Arnaud Breabout

Arnauld joined the Mundipharma network of associated companies in 2018 from GlaxoSmithKline (GSK) where he was most recently CFO Global Functions and Investments at GlaxoSmithKline (GSK).

Arnaud brings with him a wealth of international healthcare and FMCG experience gained over 20 years of service with leading pharmaceutical companies.  While at GSK, he held a number of senior finance leadership roles including VP Pharmaceutical Pipeline, CFO Biopharmaceuticals and CFO Vaccines North America. Before joining GSK in 2002, Arnaud held positions at Procter & Gamble, Bristol Myers Squibb and Price Waterhouse in France and the UK.

Arnaud gained an MBA from Amiens Business School in France, with a Major in Finance; holds the DECF (French Diploma of Chartered Accountancy) and also graduated from Harvard Business School’s General Management (GMP) Programme. Arnaud is married with three children and speaks five languages.

Chris Surridge

Chris brings an invaluable mixture of sales, business development, market access and commercialization expertise to his recent appointment as the European Director of Strategy and Commercial Excellence at Mundipharma. In this newly created role he is responsible for ensuring commercial excellence across our proven commercial platforms in specialist-driven primary care and specialty care, including our market leading biosimilars business in Europe.

Having started his pharmaceutical career in sales at Smiths Medical, Chris quickly progressed through positions of increasing responsibly with Cardinal Health, before joining Mundipharma as a Senior Business Development Manager in 2009. Since that time, he has excelled in various roles across the European network of independent associated companies including primary care sales in the UK, market access in the Netherlands and Director of the UK primary care business unit.

He holds a degree in International Business from Loughborough University Business School in the UK.

Marco Cerato

Marco joined the Mundipharma network of independent associated companies in 2018 further enhance our external partnerships and medicine pipeline.  Prior to joining Mundipharma Marco was Head of Business Development and Licensing at Helsinn and previously served as Head of Licensing for late stage assets since January 2016. Marco has significant commercial, development and strategic leadership expertise from an 11-year career in the pharmaceutical industry, with a specific focus on cancer supportive care and oncology. In his tenure at Helsinn he oversaw more than 50 licensing deals covering more than 190 countries around the world across cancer supportive care and oncology.

Marco holds a degree in Biotechnologies and a specialisation in industrial biotechnologies completed by an executive made to measure Master course in Business Administration from the Bocconi School of Management

Patrice Grand


Patrice has a broad base in communications and public affairs, gained from over 30 years of pharma experience across Europe, the United States, Asia Pacific and Latin America. He has held a series of high-profile roles including most recently Global Head of Communications, Healthcare for Merck, where he made a significant impact on the company’s corporate profile while supporting the transformation of the organisation. Previously, he was Head of International Public Affairs at Bristol-Myers-Squibb. Prior to this, he worked in different sales and marketing roles, including a stint as Director of the Healthcare Practice in Europe at renowned communications agency Burson-Marsteller.

Alfonso Camba

Alfonso has over 38 years of relevant experience (primarily in Technical Operations) in Pharma, Biotech and Advanced Therapies.  Most recently he worked in Paris as SVP Technical Operations at Stallergenes Greer, a worldwide leader in the fields of Immunology and Allergy. Previously, over a twelve-year period, Alfonso held various positions with Serono, in multiple countries. Alfonso holds a Bachelor Degree in Pharmacy, an MBA and undertook a Business Development Program in Babson College, Massachusetts.

Julie Ducharme

Julie leads research and development for the Mundipharma network outside the US, guiding a portfolio of medicines through clinical trials to registration and reimbursement.

She joined Mundipharma from Purdue Pharma Canada where she was Vice President, Research and Development. Previously, Julie led the research and development of biologics and vaccines as General Manager of Human Health Therapeutics at the National Research Council of Canada (NRC), transforming it into one of NRC’s leading portfolios. Her move to the NRC followed almost 16 years at AstraZeneca in senior leadership roles building and leading cross-functional international teams. Earlier in her career, Julie spent nine years in clinical research in academia and the pharmaceutical industry.

Julie is also an adjunct Professor of Pharmacy at the Université de Montréal and sits on several scientific advisory boards. She holds a PhD from the University of Montreal, Canada, post-doctorates from Université Paris VI, France, and McGill University, Canada, and is fluent in both French and English.

Patricia Kitchen

Patricia has been with the Mundipharma network of independent associated companies since XX date, and was appointed Global Head of Technical Services in 2016. Patricia oversees Global Technical Services which includes: Pharmaceutical Technology, Pharmaceutics / Analytical Development, Packaging Development Design, Technical Services, Technical Development and Process Engineering across the entire network of the independent associated companies.

Having starting her biotechnology career in custom antibody development, Patricia quickly progressed through research and development positions with increasing responsibility within Covance Research Products.  Patricia continued to enhance her biotech development experience by leading teams within larger corporations such as: Centocor, Inc (subsidiary of Johnson & Johnson) and Bristol Myers Squibb. She then transitioned to the pharmaceutical industry by taking an executive role at Watson Pharmaceuticals, eventually becoming Actavis, Inc and Teva Pharmaceuticals.

Patricia was an adjunct Professor in Biotechnology and currently participates on several FDA Development Taskforces focused on Patient Drug Development, Biotechnology Development and Transdermal Product Development.  She holds degrees from Arizona State University in Tempe, Arizona.

Thomas Mehrling

Thomas joined the Mundipharma network in 2000 and has held various positions during his time working for the network. He brings over 21 years of experience in pharma to his current role.

Mundipharma EDO was founded in 2013 and manages the development process of early-stage oncology assets, for the Mundipharma network.

Prior to joining the network, Thomas worked for a Global CRO where he held the position of VP Medical and Regulatory Affairs. Before this, he worked for Takeda Research & Development Centre Europe where he was responsible for the pan-European development of three new chemical entities.

Thomas is a board-certified pharmacist/pharmacologist and obtained his PhD in pharmacological science based on pre-clinical research in serotonin-receptor antagonists for the treatment of nausea and vomiting caused by chemotherapy.

He also is a board-certified physician and holds a medical doctor degree of the University of Frankfurt. He specialised and worked for several years in cardiology, hematology/oncology, and pediatric oncology.

Philippe Mazas

Philippe has amassed experience across a range of industry sectors. He was most recently with FTSE 100 global medical technology company Smith & Nephew plc, where he was Group CIO. Before that, Philippe was Group CIO at the specialist insurer Beazley Group plc. He began his career in the automotive sector, taking various positions in the Renault Group, including Regional CIO for South America, where he was based in Curitiba, Brazil. Philippe then moved to the UK to become Information Officer in charge of sales and marketing systems for General Motors Europe.

In his current role, Philippe is accountable for the IT services provided to the global network of independent associated companies.

He was educated in France and holds an engineering degree from École Centrale de Paris and a PhD in technology from Université Paris VI, France. Philippe is married with four children and is fluent in four languages.